High-dose therapy supported by autologous stem cell transplantation (HDT/ASCT) is frequently utilized in follicular lymphoma (FL) patients and has contributed to modifying the natural history of the disease [1, 2] . However, a key concern following HDT/ASCT is the occurrence of secondary malignancies. The reported incidence varies between studies, in part due to cohort differences in terms of age, pre-ASCT treatment, use of total body irradiation (TBI)-based conditioning regimens, or length of follow-up, rather than due to differences in the procedure itself [3] [4] [5] [6] [7] [8] [9] . The risk of secondary malignancies following HDT/ASCT in patients with non-Hodgkin lymphoma (NHL) has been specifically described in some papers [3-5, 7, 8] , with reported 10-year cumulative incidences ranging from 5 to 21% and a 1.6-fold to 3.3-fold greater risk of secondary malignancies compared to the general population. This is primarily driven by the risk of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), which is higher in NHL patients receiving HDT/ASCT compared to those treated with conventional therapy; by contrast, an increased risk of solid malignancies has been demonstrated only in some studies but not others [4, 7, 8, 10] . Nevertheless, the incidence of secondary malignancies following non-transplantation therapy is also higher among patients [14] . Additionally, we assessed the risk of malignancies in the general population using the International Agency for Research on Cancer GLOBOCAN database (year 2012), which includes aggregated data from 12 Spanish cancer registries (covering 21% of the population) for the period 2006-2007 [15] (http://globocan.iarc.fr/Defa ult.aspx). We determined the standardized incidence ratio (SIR; ratio of observed to expected malignancies) for the FL patient population by dividing the number of observed secondary malignancies with the number of expected cases in an age-and sex-matched cohort in the general population. Non-melanoma skin cancers (NMSC) were excluded from SIR analyses because these events are not collected in the GLOBOCAN database. The study cohort had a cumulative follow-up of 7578 patient-years.
Baseline demographic and disease characteristics, data on patients' treatment, and analyses of OS have been reported previously [14] . Interestingly, of the 655 FL patients who received an HDT/ASCT, 52% received the transplant in either first complete response (n = 203) or first partial response (n = 140). Overall, 273 patients (42%) relapsed following HDT/ASCT (median time to relapse, 1.9 years; interquartile range (IQR), 1.0-3.6 years) and received additional chemotherapy. As progenitor stem cells, 86% of the patients (517/604) received peripheral blood and the remaining 14% (87/604) bone marrow. Median follow-up from HDT/ASCT was 12 years. A total of 83 patients (12.75%) developed 85 secondary malignancies. The median age of these patients at the time of diagnosis of a secondary malignancy was 54.8 years. Of the 85 secondary malignancies there were 45 cases (53%) of solid tumors, including 5 NMSC, 34 cases (40%) of AML/MDS, 2 cases (2%) of acute lymphoblastic leukemia, 1 case (1%) each of chronic myeloid leukemia and Hodgkin lymphoma, and 2 cases (2%) of other cancers. The most frequent solid neoplasias were lung cancers followed by gastro-intestinal tract, skin, head and neck, breast and prostate cancers. In the 184 patients who receive rituximab before HDT/ASCT a total of 23 patients (12.6%) developed a secondary malignancy (12 solid tumors and 11 AML/MDS). The median time from HDT/ASCT to diagnosis of any secondary malignancy was 5.5 years (IQR, 3.1-9.8), and to diagnosis of a secondary solid tumor or AML/MDS was 7.7 years (IQR, 3.2-9.9) and 4.2 years (IQR, 2.4-7.3), respectively. The cumulative incidence of any secondary malignancy at 5, 10, and 15 years was 6.6, 13.0, and 17.5%, respectively, and was 2.5, 4.9, and 9.6% for solid tumors and 2.5, 6.8, 8.3% for AML/MDS. In the univariate analysis, only male sex (P = 0.02) and age >45 years at HDT/ASCT (P = 0.04) were associated with an increased risk of secondary Results are presented as Hazard ratio (95% confidence interval). SIR standardized incidence ratio, HDT/ASCT high-dose therapy supported by autologous stem cell transplantation, CR complete response, TBI total body irradiation, PB peripheral blood, BM bone marrow, PR partial response, FL follicular lymphoma malignancies. The use of rituximab prior to HDT/ASCT and achievement of a response less than complete response prior to HDT/ASCT appeared to show a trend towards an increased risk of secondary malignancies (P = 0.07 and 0.06, respectively). The SIR for any secondary malignancy in the FL patient population compared to the expected rate of malignancies in an age-and sex-matched cohort of the general population was 3.11 (95% CI, 2.9-3.7; P < 0.0001) ( Table 1 ). The respective SIRs for solid tumors was 1.42 (95% CI, 1.3-1.6; P = 0.04) The SIRs for the most important patient-, disease-, and treated-related parameters are shown in (Table 1) . Elevated risk for second neoplasia was pronounced in all the subgroups.
In a Kaplan-Meier analysis, among the 83 FL patients who developed secondary malignancies, the median OS from the time of FL diagnosis was 12 years, and from the time of HDT/ASCT was 9.4 years (median of 14.5 years in patients developing secondary solid tumors vs. 8 years in patients developing AML/MDS; P = 0.01). The median survival from the time of diagnosis of any secondary malignancy was 1.5 years; median survival was 2.3 years in patients developing secondary solid tumors and 1.25 years in patients developing AML/MDS (P = 0.01) (Fig. 1) . This analysis demonstrated an overall incidence of secondary malignancies of 12.75%, with a cumulative risk at 10 years of 13.0% overall and of 4.9 and 6.8% for solid tumors and AML/MDS, respectively. Our FL patient population had a 3.1-fold greater risk of developing a secondary malignancy compared to the general population, with a 1.42-fold increased risk of developing a solid tumor. Our findings also highlight the dismal prognosis following the diagnosis of a secondary malignancy, with a median survival of only 1.25 years for patients developing secondary AML/MDS.
The increased risk of developing AML/MDS in lymphoma patients post-HDT/ASCT compared to general population is well established [4, 5] . Additionally, the plateau in the cumulative risk of AML/MDS in the present analysis, with the last case occurring 7 years after HDT/ ASCT, has also been demonstrated in NHL patients who have undergone HDT/ASCT [4] . This plateau reflects the known shorter latency period of secondary AML/MDS compared to secondary solid tumors [4] . The cumulative incidence of secondary solid tumors in our analysis was lower than that reported in a series of 605 patients with Bcell NHL who received HDT/ASCT with a TBI-containing regimen [3] , and comparable to that reported with conventional chemotherapy [12] . The overall risk of developing secondary solid tumors was only slightly higher than in general population, probably because most of the FL patients underwent HDT/ASCT early in the course of their disease.
In the global analysis, as expected, male sex and older age (>45 years) were associated with a higher incidence of second malignancies. Nevertheless, in the SIR analysis there was a higher risk from secondary neoplasia in young patients (Table 1) . According to the published data [4] , in our analysis, the use of rituximab before HDT/ASCT showed a tendency to increase the risk of secondary solid tumors.
Although these data do not demonstrate whether the increased risk of secondary malignancies is directly due to HDT/ASCT, they do reflect the findings from other recent analyses. A systematic review and meta-analysis of randomized controlled trials comparing HDT/ASCT with other treatment modalities in patients with lymphoproliferative diseases (16 trials, 3343 patients) [6] demonstrated a higher risk of secondary malignancies (RR = 1.6) following HDT/ ASCT, but only for secondary AML/MDS (RR = 2.35) and not secondary solid tumors (RR = 1.06)
Our study has a number of limitations, including the retrospective design, the heterogeneous disease status of the patients undergoing HDT/ASCT, and the heterogeneous treatment regimens received before and after HDT/ASCT, as well as the lack of a control group of FL patients who did not undergo HDT/ASCT. Nevertheless, the findings are valuable as the lengthy follow-up period provides sufficient time to evaluate the association between HDT/ASCT and the development of secondary solid tumors. Additionally, the analysis specifically focuses on FL patients, and includes a considerable proportion of patients (30%) treated in the rituximab era [14] .
In conclusion, our analysis demonstrates that the risk of secondary malignancies, especially AML/MDS, is increased in this large series of FL patients undergoing HDT/ASCT, compared to the general population. Moreover, the prognosis after the diagnosis of a secondary malignancy is dismal. Nevertheless, given the curative potential of HDT/ASCT in FL we suggest that HDT/ASCT should be still used in specific treatment settings.
